Pharmaceconomical Efficacy Analysis of Antiplatelet Therapies in Patients after PCI

OBJECTIVE To compare the pharmaceconomical efficacy of three antiplatelet treatments after percutaneous coronary intervention (PCI) from the perspective of health care.METHODS Patients were given domestic clopidogrel routinely, ticagrelor routinely,domestic clopidogrel or ticagrelor guided by CYP2C19 genotype testing,which all were combined with aspirin.A decision-analytic model was established to predict the rate of avoiding the major cardiovascular event and cost and the following time was one year.RESULTS Although the treatment of domestic clopidogrel plus aspirin routinely was the lowest cost option,the cost-effectiveness of ticagrelor combined with aspirin routinely was the best.CONCLUSION Routine ticagrelor combined with aspirin is recommended for patients after PCI.